igella sativa extract and depressio
Phase 2
- Conditions
- Depression.Major depressive disorder, recurrent, mildF33.0
- Registration Number
- IRCT20200217046523N17
- Lead Sponsor
- Artesh University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age between 18 and 65 years
Having Major Depression
Referring to the 505 Artesh Hospital
Treated only with sertraline
Moderate to severe depression
Having the written informed consent to participate in the study
Exclusion Criteria
Failure to take medication regularly
Drug intolerance
Allergy to Nigella sativa
Having systemic diseases
Pregnancy or breastfeeding in women
Tendency to leave during the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of depression. Timepoint: At the beginning of the intervention and 6 weeks after treatment. Method of measurement: Using Depression, Anxiety and Stress Scale - 21 (DASS-21).;Serum levels of Brain-Derived Neurotrophic Factor (BDNF). Timepoint: At the beginning of the intervention and 6 weeks after treatment. Method of measurement: By enzyme-linked immunosorbent assay (ELISA) kits.
- Secondary Outcome Measures
Name Time Method